RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

NCT05821933 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: RC108

Sponsor

RemeGen Co., Ltd.